Progress in cancer research is happening at an unprecedented pace and, as we gain more knowledge and develop more therapeutic options, we face new challenges. One of the biggest challenges remains to develop approaches that can be translated to the clinic and speed up the process of turning exciting discoveries into effective therapies.
This one-day virtual event (the second in our Beyond the Horizon series) aims to identify and address current and future challenges in translational cancer research specifically in the context of pre-clinical development to early phase clinical evaluation. Following an initial overview of the status quo and a definition of translation across the research spectrum, delegates will hear from eminent speakers in a series of panel discussions where specific topics will be addressed. These topics have been identified through a series of interviews with cancer researchers and distilled by a Scientific Committee.
By the end of the day, delegates will have learnt about what we need to know and do to address this translational gap and prepare for the future, how we can work together to achieve a greater impact and improved patient benefits, as well as the case for change in certain areas of research.
- Professor Tim Maughan – NCRI, UK
- Professor Ian Campbell – Peter MacCallum Cancer Centre, Australia
- Dr Samra Turajlic – The Francis Crick Institute, UK
- Professor Ruth Plummer – Newcastle University, UK
- Dr Ian Campbell – Life Arc, UK
- Professor Muzlifah Haniffa – Sanger Institute, UK
- Dr Sarah Markham – King’s College London, UK
- Dr Sam Cooper – Phenomic AI, Canada
- Dr Michael Chapman – NHS Digital, UK
- Dr Stefan Symeonides – Edinburgh Cancer Research Centre, UK
- Dr Nirupa Murugaesu – Genomics England, UK
- Dr Matthew Krebs – The University of Manchester, UK
- Professor Sarah Bohndiek – University of Cambridge, UK
- Professor Michael Kent – University of California Davis, USA
- Dr Fiona Thistlethwaite – The Christie NHS Foundation Trust, UK
- Dr Eileen Parkes – University of Oxford, UK
- Dr Hamish Ryder – Cancer Research UK, UK
- Dr Tony Soteriou – UK Research and Innovation, UK
- Mr Ian Waterson – Medicines and Healthcare products Regulatory Agency, UK
5 category 1 (external) CPD for this session has been approved by the Federation of the Royal Colleges of Physicians. CPD Certificates will be sent to delegates automatically up to 10 days after the event date.
The cost of this event depends on which attendee category you fall into. Students and patient experts can attend for free. All other categories are charged between £50 – £150.
Who should attend?
Investigators and other professionals operating in translational research across the research spectrum, as well as patient experts and other professionals supporting the research efforts.
Can I watch the first Beyond the Horizon event?
Yes, a recording of ‘Beyond the Horizon: Innovative cancer drug discovery’, which took place on 26 February 2021, is available to watch on-demand. This event was held to address current and future challenges in the discovery and development of innovative drugs for cancer treatment.